Principal Financial Group Inc. Has $6.44 Million Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Principal Financial Group Inc. reduced its position in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 24.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 577,727 shares of the biopharmaceutical company's stock after selling 184,961 shares during the period. Principal Financial Group Inc. owned approximately 0.44% of Dynavax Technologies worth $6,436,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Dynavax Technologies by 1.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 118,037 shares of the biopharmaceutical company's stock worth $1,326,000 after purchasing an additional 1,172 shares during the last quarter. SummerHaven Investment Management LLC lifted its holdings in Dynavax Technologies by 2.4% in the second quarter. SummerHaven Investment Management LLC now owns 54,926 shares of the biopharmaceutical company's stock worth $617,000 after acquiring an additional 1,303 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in Dynavax Technologies by 44.6% in the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company's stock worth $61,000 after acquiring an additional 1,679 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Dynavax Technologies by 175.5% in the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 1,685 shares during the last quarter. Finally, Louisiana State Employees Retirement System lifted its holdings in Dynavax Technologies by 3.0% in the second quarter. Louisiana State Employees Retirement System now owns 65,900 shares of the biopharmaceutical company's stock worth $740,000 after acquiring an additional 1,900 shares during the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Trading Up 1.3 %

Dynavax Technologies stock opened at $12.17 on Thursday. The company has a 50 day moving average price of $11.42 and a 200 day moving average price of $11.31. Dynavax Technologies Co. has a 52 week low of $9.74 and a 52 week high of $15.01. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of 93.62 and a beta of 1.34.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. HC Wainwright restated a "buy" rating and issued a $29.00 price target on shares of Dynavax Technologies in a research note on Friday, November 8th. The Goldman Sachs Group decreased their price target on shares of Dynavax Technologies from $20.00 to $15.00 and set a "neutral" rating on the stock in a research report on Thursday, August 8th.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.